Novo, Viatris
Novo Nordisk, Viatris settle patent dispute over Ozempic, Wegovy: report
Novo Nordisk (NVO) and Viatris (NASDAQ:VTRS) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo’s popular weight-loss drugs Wegovy and Ozempic. The companies announced the settlement in a joint filing on Friday made with the U.
Novo Nordisk settles US patent fight with Viatris over Ozempic
Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and Wegovy, the companies told a U.S. Patent and Trademark Office tribunal.
Novo, Viatris Settle Ozempic Patent Row
Alongside the settlement, Novo and Viatris have asked the U.S. Patent and Trademark Office to terminate its review of the validity of the Danish drugmaker’s semaglutide patents.
Novo Nordisk (NYSE:NVO) and Viatris Settle Patent Dispute for Weight-Loss Drugs
Novo Nordisk (NVO) and Viatris (VTRS) have agreed to settle a dispute over patents for Novo’s weight-loss drugs, Ozempic and Wegovy, according to Reuters. The two companies informed the U.S. Patent and Trademark Office (USPTO) that they reached an ...
Amid GLP-1 craze, Novo and Mylan ink patent settlement in Ozempic case
With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their generic to Novo Nordisk's wildly popular type 2 diabetes drug Ozempic. | Mylan Pharmaceuticals and Novo Nordisk have reached a confidential settlement in a patent lawsuit tied to generic Ozempic,
Viatris 2023 Sustainability Report: Reducing Packaging Material
NORTHAMPTON, MA / ACCESSWIRE / October 10, 2024 / Viatris is continuously looking for ways to reduce the volume and types of ...
Is Viatris Inc. (NASDAQ:VTRS) The Best NASDAQ Stock Under $20?
We recently made a list of 10 Best NASDAQ Stocks Under $20 to Buy. In this piece, we will look at where Viatris Inc.
Viatris: EFFEXOR Meets Primary And All Secondary Efficacy Endpoints In Japan - Quick Facts
Viatris (VTRS) reported positive top-line results of Phase 3 study in Japan evaluating the safety and efficacy of EFFEXOR in adults ...
bovnews1d
Jefferies Issues Buy Rating for Viatris Inc (VTRS) Stock
On Tuesday, Viatris Inc (VTRS) stock saw a decline, ending the day at $11.32 which represents a decrease of $-0.01 or -0.09% from the prior close of $11.33. The stock opened at $11.33 and touched a ...
CSR Wire1d
Viatris Named to Forbes' Annual List of the World's Best Employers for the Fourth Year in a Row
Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to Forbes' list of World's Best Employers 2024.
Drug Store News2d
Gilead signs agreements with 6 generic manufacturers for Lenacapavir
The generic companies that will manufacture and supply Lenacapavir to 120 countries are Dr. Reddy’s, Emcure, Eva Pharma, ...
The Motley Fool3d
Viatris (NASDAQ: VTRS)
Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics ...
Khaleej Times on MSN1d
UAE: New mental health podcast to 'tear away silence' on stigma, wellness in workplace
A new mental health podcast will be coming up in the UAE soon, creating a unique advocacy platform committed to tackling the ...